MonoMAC is a dubious disease in the field of autoimmunity and rheumatic immunity, clinical performance is complex and often involves multi-system congestion. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching teams of authoritative experts at home and abroad to provide accurate diagnostics and treatment plans. Treatment and management of MonoMACs require individualized development of treatment plans, typically including drug therapy, rehabilitation interventions, and regular follow-up multidimensional management. In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many autoimmune and rheumatic immune disorders that were previously difficult to treat have been significantly improved.
Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of MonoMAC. The platform serves the China International Medical Service System, a team of nationally and internationally authoritative experts in the field of autoimmunity and rheumatic immunity, who provide the following services to patients: 1.
Remote pre-diagnosis: Pre-examination of medical records, clear diagnostic directions and medical advice by a team of experts; 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.